Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibBusiness Wire • 11/12/24
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire • 11/07/24
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialBusiness Wire • 10/23/24
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo DrugZacks Investment Research • 10/15/24
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase InhibitorBusiness Wire • 10/14/24
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual MeetingBusiness Wire • 09/30/24
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic CancersBusiness Wire • 09/23/24
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024Business Wire • 09/13/24
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib DataSeeking Alpha • 08/30/24
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioBusiness Wire • 08/28/24
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/24
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial ResultsBusiness Wire • 08/06/24
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIBusiness Wire • 06/26/24
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for LunresertibBusiness Wire • 06/12/24
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialBusiness Wire • 06/10/24
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian CancerBusiness Wire • 06/04/24
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/03/24
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024Business Wire • 05/29/24
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsBusiness Wire • 05/07/24
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionBusiness Wire • 04/30/24
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 InhibitionBusiness Wire • 04/30/24
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire • 03/21/24